Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/8/2022 | $9.00 → $1.80 | Outperform → Neutral | Wedbush |
| 3/4/2022 | $6.00 → $1.80 | Buy → Neutral | HC Wainwright & Co. |
| 10/20/2021 | $5.00 → $7.00 | Outperform | BMO Capital |
| 10/19/2021 | $5.00 → $6.00 | Buy | HC Wainwright & Co. |
15-12G - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)
EFFECT - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)
EFFECT - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)
4 - Entasis Therapeutics Holdings Inc. (0001724344) (Issuer)
4 - Entasis Therapeutics Holdings Inc. (0001724344) (Issuer)
4 - Entasis Therapeutics Holdings Inc. (0001724344) (Issuer)
SC 13D/A - Entasis Therapeutics Holdings Inc. (0001724344) (Subject)
SC 13D/A - Entasis Therapeutics Holdings Inc. (0001724344) (Subject)
SC 13D/A - Entasis Therapeutics Holdings Inc. (0001724344) (Subject)
Wedbush downgraded Entasis Therapeutics Hldg from Outperform to Neutral and set a new price target of $1.80 from $9.00 previously
HC Wainwright & Co. downgraded Entasis Therapeutics Hldg from Buy to Neutral and set a new price target of $1.80 from $6.00 previously
BMO Capital reiterated coverage of Entasis Therapeutics Hldg with a rating of Outperform and set a new price target of $7.00 from $5.00 previously
Royalties increased by 5% to $93.5 million in the first quarter of 2022, compared to the same quarter in 2021. Issued $261.0 million convertible senior notes due 2028 and repurchased a portion of the convertible subordinated notes due 2023. Invested $45.0 million into Armata Pharmaceuticals Inc. (NYSE:ARMP) ("Armata"), an anti-infectives leader. Made a non-binding offer to acquire and provided $15.0 million convertible debt financing to Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) ("Entasis"), an anti-infectives leader. Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" and "the Company") today reported financial results for the first quarter ended March 31, 2022. Gross royalty revenue
Sulbactam-durlobactam (SUL-DUR) achieved all primary and secondary endpoints from landmark Phase 3 ATTACK trialRobust dataset builds compelling case for SUL-DUR which if approved, could become the first, uniquely differentiated and life-saving treatment option for patients with Acinetobacter infectionsPreparing for commercialization ahead of NDA submission in mid-2022, under the leadership of newly appointed Chief Commercial Officer Anna Diaz TriolaEntasis' pathogen-directed platform and latest candidate ETX0462 highlighted by seminal publication in the prestigious scientific journal Nature WALTHAM, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX),
WALTHAM, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that management will report third quarter 2021 financial results before the market opens on November 4, 2021. The company will host a conference call and webcast at 8:00AM Eastern Time to discuss its results and provide a clinical and corporate update. A question-and-answer session will follow management's prepared remarks. Investors and the general public are invited to listen to a live audio webcast of the conference call, which may be accessed five min
– Significant commercial strategy and product launch experience –– ATTACK Phase 3 top-line data readout remains on-track for 2H 2021 – WALTHAM, Mass., July 14, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today the appointment of Anna Diaz Triola as Chief Commercial Officer, effective July 19th 2021. Ms. Triola will be responsible for global commercial strategy, including U.S. sales and marketing operations. "With the ATTACK Phase 3 registration clinical trial nearing completion, we are now engaged in preparing for commercialization
WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc., a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, and wholly owned subsidiary of Innoviva, Inc. (NASDAQ:INVA), today announced that six abstracts highlighting sulbactam-durlobactam (SUL-DUR) have been selected for presentation at IDWeek 2022, the annual meeting of the Infectious Disease Society of America taking place October 19-23, 2022 in Washington, D.C. Details of the presentations are as follows: Oral Presentations: Title: Microbiologic and clinical outcome concordance in the global phase 3 ATTACK trial: sulbactam-durlobactam
Innoviva, Inc. (NASDAQ:INVA) ("Innoviva") today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) ("Entasis") at a price of $2.20 per share, net to the seller in cash, without interest and less required withholding taxes, expired at 5:00 p.m. New York City time on Thursday, July 7, 2022. The depositary for the tender offer has advised that, as of the expiration of the tender offer, a total of 11,671,662 shares of Entasis' common stock were validly tendered and not withdrawn in the tender offer. Such shares of Entasis' common stock, upon excluding those tendered by Manoussos Perros (the "
WALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced multiple presentations at the American Society for Microbiology (ASM) annual Microbe conference, taking place June 9-13, 2022, in Washington, DC. Entasis is presenting data on sulbactam-durlobactam (SUL-DUR), an investigational drug in development for the treatment of infections caused by Acinetobacter baumannii including carbapenem-resistant and multidrug-resistant (MDR) strains, and ETX0462 a novel, first-in-class, diazabicyclooctane with broad spectrum